Brought to you by 
Evotec acquires Oxford Asymmetry
20 Feb 2002
Executive Summary
Evotec BioSystems (develops drugs for unmet medical needs) has acquired Oxford Asymmetry International (UK discovery services company). Shareholders will receive 0.1287 of a new Evotec share for each OAI share, valuing the stock swap at $475mm (UK316mm). OAI shareholders will own about 31% of the new company.
Deal Industry
- Biotechnology
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com